Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jul 27, 2025 | Carillon Eagle Small Cap Growth Fund | - | - | AEI, ARIS, ATI, BOOT, BRBR, CLBT, MMSI, SHAK, VNOM, WWD | earnings growth, Recovery, selectivity, small caps, volatility | The commentary emphasizes small-cap recovery potential supported by improving earnings visibility. Management highlights selectivity amid policy and rate uncertainty. Small-cap growth is viewed as attractive for long-term investors. | MMSI BRBR CLBT VNOM ARIS BOOT AVAV ATI WWD SHAK |
View |
| 2025 Q2 | Jul 21, 2025 | Wasatch Small Cap Growth Strategy | - | - | AGYS, BRBR, CWAN, FN, GSHD, NVMI | earnings momentum, free cash flow, growth, Quality, small cap | The strategy emphasizes high-quality small-cap growth companies with proven earnings momentum. Short-term headwinds from tariffs and speculative trading masked underlying business strength. Long-term confidence remains anchored in fundamentals and free cash flow generation. | GSHD |
View |
| 2025 Q4 | Feb 3, 2026 | John Hancock Balanced Fund Class I | 3.7% | 16.0% | AAPL, AMZN, AVGO, BRBR, FCX, GOOGL, JPM, LLY, MSFT, ZBRA | asset allocation, Balanced, equities, fixed income, healthcare, materials, security selection, technology | Eli Lilly & Company contributed to relative performance with shares rising amid continued growth in its GLP-1 drug franchise. Freeport-McMoRan benefited from rising copper and gold prices, contributing to fund performance. | View | |
| Q4 2025 | Feb 3, 2026 | Baird Small/Mid Cap Growth Equity Fund | 1.2% | -8.5% | ABT, AFRM, BOOT, BRBR, BROS, BURL, BWXT, CASY, CHDN, COCO, CRDO, CW, DKNG, DT, ELF, EME, EXAS, FOUR, GKOS, KTB, LII, MASI, MNDY, MTSI, PEN, PODD, RGEN, RKLB, TARS, TWLO, ULS, VERX, WAY, WSO | AI, defense, growth, healthcare, mid cap, semiconductors, small cap, technology | The extended federal government shutdown added volatility during what was otherwise a risk-on environment, with a mid-quarter shift in market behavior for AI-related equities as the exuberant narrative evolved to one more balanced in assessing the technology's enormous potential against staggering capital spending plans and high expectations. The team initiated a position in Credo Technology as a more diversified way to gain exposure to strong trends in AI-connectivity. MACOM Technology Solutions rose nearly +40% as the company experienced broad-based demand, similar to many semiconductor companies in 2025. The team exited Astera Labs following industry conference presentations that suggested emerging competitive risks and concerns over single customer concentration, while initiating a position in Credo Technology for AI-connectivity exposure. Healthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. The team initiated a position in Curtiss-Wright, believing the company is entering a period where multiple near-term growth drivers are converging, including rising defense budgets, commercial aerospace production ramps, nuclear power plant life extensions and new builds, and submarine production. EMCOR Group was initiated as a new position, viewed as a critical contractor enabling multi-year investment cycles across data centers, semiconductor fabrication, electrification, and broader infrastructure modernization. Its decentralized, cash-generative model, recurring service base, and exposure to structural growth drivers create a profile viewed as more durable than a typical cyclical contractor framework. | View | |
| 2024 Q4 | Dec 31, 2024 | Wasatch Small Cap Growth Strategy | 1.7% | 15.2% | BOOT, BRBR, PACS, PCTY, ROAD, TMDX | - | View | ||
| 2023 Q4 | Dec 31, 2023 | Wasatch Small Cap Growth Strategy | 7.6% | 7.6% | BRBR, FOXF, MEDP, PCTY, PNFP, XPEL | - | View | ||
| 2025 Q3 | Nov 11, 2025 | Prosper Stars & Stripes | 9.8% | 8.6% | ARX, BRBR, GDYN, KLG, PKE, TATT | cyclicals, earnings, Recovery, small caps, Valuations | The letter emphasizes that small caps are positioned for a multi-year recovery as earnings trends broaden beyond AI-driven megacaps and benefit from monetary easing, fiscal stimulus, and depressed sentiment. The manager argues that small-cap valuations remain highly attractive after an extended underperformance cycle, with improving fundamentals expected in 2026 as earnings recover across cyclical sectors. Policy tailwinds, productivity gains, and stabilization in economic indicators reinforce the case for renewed small-cap leadership. | TATT |
View |
| 2025 Q3 | Oct 24, 2025 | Carillon Eagle Small Cap Growth Fund | - | - | BRBR, LNTH, MMSI, MNDY, PI, POWL, PRM, RMBS, SHAK, ZWS | AI, cyclicals, energy, industrials, small caps | The fund outperformed amid small-cap strength and AI-related industrial demand. Top contributors included Rambus and Impinj, both benefiting from hyperscaler and RFID adoption. Managers expect AI and data center capex to sustain industrial growth, while cyclical tailwinds in energy and reshoring enhance long-term fundamentals. | ZWS PRM PI RMBS |
View |
| 2025 Q3 | Oct 20, 2025 | Wasatch Small Cap Growth Strategy | -3.7% | - | BRBR, FN, INSP, MEDP, NVM, SHAK | Artificial Intelligence, Growth Investing, healthcare, semiconductors, small caps | The fund underperformed as small-cap volatility and speculative AI stocks distorted relative performance. Managers emphasize high-quality, long-duration growth companies like Medpace and Nova that benefit from structural healthcare and semiconductor trends. They remain confident in small-cap fundamentals and expect normalization as low-quality rallies fade. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Fund Letters | Eric Mintz | BellRing Brands, Inc. | Consumer Staples | Packaged Foods & Meats | Bull | NYSE | Beverages, brands, consumer staples, Inventory, Protein | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||